Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. - Wikidata - awgldk - TriplyDB

Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

http://www.wikidata.org/entity/Q30620658

about

Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia.Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Molecular therapy for acute myeloid leukaemia.Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide Advances in treating acute myeloid leukemia.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia.The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia Acute myeloid leukemia and myelodysplastic syndromes in older adults.Targeted therapy of acute myeloid leukemia.Elderly acute myeloid leukemia: assessing risk.Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors.Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia.Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.CpG island methylator phenotype and its relationship with prognosis in adult acute leukemia patients.Expert insights into the contemporary management of older adults with acute myeloid leukemia.The impact of remission status on patients' experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.Toona sinensis Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo.Improved outcome for AML patients over the years 2000-2014.Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.CDK9 inhibitors in acute myeloid leukemia.Initial therapy for acute myeloid leukemia in older patients: principles of care.Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.Incidence and survival of hematological cancers among adults ages ≥75 years.Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia.

P2860

Q27336142-1304ACEE-F8DF-4108-91D1-11D4E2DA0A04 Q28084813-5C1DB2D1-E534-46F5-B752-8C028317CAE6 Q33417145-FF584D70-11B1-4303-9E45-8CA8516697DE Q33707331-6999A25F-9F09-480D-BC76-F19925497457 Q33840247-904FF1A9-BC9D-4ADE-BB1B-DCA048136352 Q33925672-557409A3-0A6F-4545-A2A0-3654921D1461 Q34121354-E45C28C2-EFDB-41D9-99DC-92924C871605 Q34312351-6700AFF7-6F43-4E99-8AB0-F1220E3CB0BA Q34428556-AE0EB7BB-DA9D-44B9-91C2-14346ADAC454 Q36107268-EACA492F-2618-49D3-A68B-A9AD54D89EF1 Q36279306-619E546B-0C0F-4EB3-85D5-1B1C2F917A20 Q36723291-9A464239-69AF-4D11-9195-CB20FF8097F3 Q36742031-CF45C02F-1BB6-4294-B6CC-44552E4B6A5B Q36866323-7BE0CF69-D100-434C-B933-F0000971A11B Q38234863-2BAB457B-56A4-45A1-989F-F13534417B8A Q38333251-C570192B-C4AE-4400-855D-CBE3EB27402C Q38458166-ACD49F88-6C26-4693-8C1D-B0BC84319D1A Q38797003-680DBD6E-3E9B-4B52-A3B1-021186CCA095 Q38918850-1B26617D-EF97-4C30-B50E-89FDAAF0D015 Q38967020-AD59AD66-0838-4715-A453-3A254AE46F58 Q39311595-178694F3-751E-4DDA-8679-C3DE7945ADD6 Q39342733-03AD7149-0C77-418E-9FDB-BFAC5746F491 Q40376093-7D60F7AD-E1B2-4935-A76E-DCE5435518C6 Q40548451-D15F27BB-2114-4707-A0CF-FD05F3591445 Q40727176-20EB66F9-FD1F-49C7-9CC0-724810DBFE70 Q43649407-84B08491-C0E1-45E9-A8E4-02907EDA14AD Q44898238-ADEE3C87-CE46-49FF-896A-A3C91F0124BD Q47450476-342577AC-CE16-465C-A543-EFE253D36526 Q48154329-584EDE3F-A134-448A-8BBD-B07B38FC8AF3 Q49221676-E8BDEE28-AF78-483D-9E2F-CE1110857E3B Q49566124-A2CDEC23-AF18-4D71-ACC6-F7125C3C60F6 Q50028184-45DF1381-034F-4281-A3C8-B7F209BF6A0D Q50318294-DC68921B-C3C7-4FA4-B6F9-FE4638D7C747 Q52767299-67EE3E03-DA1F-4CF8-9C09-F28E982C26B3 Q52867206-34603228-AD00-4E15-AA24-D36B5E6EB1EA Q54212475-67CBE0BE-F34A-4C03-AB34-F4788CEAA059 Q54342150-4AC56156-ED6B-450D-9625-7BE494287A31 Q55355645-BF2883CB-A4D7-4E45-8CB1-156941B1E12E

P2860

Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

http://www.wikidata.org/entity/Q30620658

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Outcome of older patients with ...... s of SEER data over 3 decades.

@ast

Outcome of older patients with ...... s of SEER data over 3 decades.

@en

type

label

Outcome of older patients with ...... s of SEER data over 3 decades.

@ast

Outcome of older patients with ...... s of SEER data over 3 decades.

@en

prefLabel

Outcome of older patients with ...... s of SEER data over 3 decades.

@ast

Outcome of older patients with ...... s of SEER data over 3 decades.

@en

P1433

Q30620658-ACDB6A1C-6C21-4A3A-9558-540F4D88DBC1

P1476

Q30620658-5D358E3A-6A51-4D0D-B96E-D624FBEE4EFC

P2093

Q30620658-0E2D7F6C-BC9B-4371-AFEB-71EFA63CD56B

Q30620658-356F95BA-C22D-46D7-B871-5FDD229C3FFB

Q30620658-9D9DDAA1-2345-4246-8C40-C203E00CD7D3

Q30620658-B20B4C11-D3A5-4FA9-9A5D-E5BC0009A4B4

Q30620658-E0E86851-2926-4C89-836A-CF5F2CE4F309

P2860

Q30620658-0EE7308C-5EBF-4349-8EA1-533F859DA9B5

Q30620658-0F89435E-9832-4A4A-A3FD-8C08AAF9BCA6

Q30620658-19031C85-946F-40E6-8475-375B4D51ADA8

Q30620658-1C9985D5-2376-4E2F-AB0B-4B0180A3177D

Q30620658-1F59366E-45B3-41E6-A7E4-BF0407C66175

Q30620658-2ED872AA-0ED1-44A1-9EE5-7B7FFA45824B

Q30620658-53D7A30B-D4BA-4FEA-A0DB-9AEDEF966D5B

Q30620658-5696BB86-C8FE-4BE4-955A-178106810294

Q30620658-6B8289B6-7037-42B2-B72B-DFFFF86F2053

Q30620658-80A22690-7932-4DFC-9042-86D462C00AC5

P304

Q30620658-65698114-38E5-442E-91D7-06DE848E30E6

P31

Q30620658-ADAC2FC1-9A29-4527-8831-CA1645CF181D

P356

Q30620658-775FE099-6374-46FC-A8B9-F5409C083C57

P407

Q30620658-4AC59962-7DD3-4435-B052-1C10437AF1B1

P433

Q30620658-644A0D79-D597-4923-A5F3-602200CEC9B4

P478

Q30620658-B5DABAE6-50A8-42E7-AF75-AEFA4FCB6E65

P577

Q30620658-5B56F601-B093-428D-80A7-6DA86EA439E0

P698

Q30620658-F616E80E-20C6-45A8-AFB7-835C8AC13FFD

P921

Q30620658-435DAB44-6669-4F9F-BE7B-1349B27CF158

P932

Q30620658-5615B008-AA01-4C80-AB4B-179323C9BB65

P356

P1433

P1476

Outcome of older patients with ...... s of SEER data over 3 decades.

@en

P2093

Ahmedin Jemal

http://www.w3.org/2001/XMLSchema#string

Jerome W Yates

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

Mya S Thein

http://www.w3.org/2001/XMLSchema#string

William B Ershler

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications.

A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.

Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Interpreting trends in cancer patient survival.

Age and acute myeloid leukemia.

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

High-dose daunorubicin in older patients with acute myeloid leukemia.

P304

2720-2727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28129

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23633441

http://www.w3.org/2001/XMLSchema#string

P921

P932

3821042

http://www.w3.org/2001/XMLSchema#string